Mutant antibodies and conjugation thereof

US11780935B2 · kind B2 · utility

Assignee

• Pfizer Healthcare Ireland · IE

Inventors

• Olivier Alexandre Laurent · San Diego, US
• Alice Lee · Poway, US
• Richard Ryan Preston · Escondido, US
• David Tumelty · Sunnyvale, US
• Wei Yu · Montclair, US
• Abhijit Suresh Bhat · Cambridge, US
• Anna Tempczyk-Russell · San Diego, US

Key dates

• Filing date: Jun 9, 2020
• Grant date: Oct 10, 2023
• Expiry date: Oct 18, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a polypeptide comprising 7 β-strands A, B, C, D, E, F, and G sequentially connected together by connecting chains of amino acids, and a first α-helix sequentially located on the EF chain between β-strands E and F, wherein the β-strands are arranged so as to form a first β-sheet comprising β-strands A, B, D, and E, and a second β-sheet comprising β-strands C, F and G, said first and second β-sheets being covalently bonded together so as to form a first Ig domain; wherein the EF chain between β-strands E and F comprises the sequence X1-X2-X3-X4-K5H6 (SEQ ID NO:98), and X1, X3 and X4 are each independently any amino acid residue, characterized in that X2 is selected from the group consisting of A, G, I, V, L, R, S, T, Q, P, N, M, H, W, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, and prodrugs thereof.